한국 소아 염증성 장질환 환자의 질병, 치료 양상 및 의료 이용에 대한 데이터베이스 연구 (Ped IBD Claims)
대한민국 소아청소년(18세 미만) 염증성 장질환 환자의 역학, 치료 패턴 및 의료 자원 활용: 청구 데이터베이스 연구
The purpose of this study is:
- to find out out the number of children who develop crohn's disease (CD) and ulcerative colitis (UC) each year and are living with the disease and to see how this differs by age groups.
- to understand how children of different age groups are treated over time and how their treatment changes as they grow.
- to assess how often children use healthcare services and how much this costs for different age groups over several years.
CD and UC are long-term diseases that cause inflammation in intestine (part of digestive system) and develop ulcers.
연구 개요
상태
정황
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
-
Suwon, 대한민국, 16419
- Sungkyunkwan University Research and Business Foundation
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population will be selected from the health insurance review and assessment (HIRA) database and include pediatric participants, who have been newly diagnosed or previously with either crohn's disease (CD) or ulcerative colitis (UC).
설명
Inclusion Criteria:
- Participants with at least two outpatient or one inpatient diagnosis codes for the same disease type (either CD or UC) using international classification of diseases, tenth revision (ICD-10) codes (K50. X for CD and K51. X for UC) recorded as primary or the first secondary diagnosis, and the codes for rare and intractable disease registration program (V130 for CD, V131 for UC) during the index period
- Participants who received at least one prescription for conventional pediatric inflammatory bowel disease (IBD)-related medications (for example, 5-aminosalicylic acids [5-ASAs], exclusive enteral nutrition [EENs], corticosteroids, immunomodulators, or biologic drugs) during the index period
Exclusion Criteria:
- No specific exclusion criteria are defined in this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: RETROSPECTIVE
코호트 및 개입
그룹/코호트 |
|---|
|
Group 1: Newly and Previously Diagnosed Pediatric Inflammatory Bowel Disease (IBD) Participants
Participants, who have been either newly diagnosed or previously diagnosed with Crohn's disease (CD) or Ulcerative colitis (UC) will be enrolled. Data will be analyzed for epidemiology, baseline demographics and clinical characteristics, health care resource utilization profiles, and associated costs. Only newly diagnosed participants will be included in the analysis of longitudinal treatment patterns and incidence estimation. Only data available per routine clinical practice will be used in this study and will be de-identified and extracted from the health insurance review and assessment (HIRA) database. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Crude and Age-Adjusted Annual Incidence in Pediatric Crohn's Disease (CD)
기간: During the index period (2012 to 2023; up to 12 years)
|
The crude and age-adjusted annual incidence CD will be calculated in each calendar year. Annual incidence and the prevalence in the year of interest will be estimated using the number of newly diagnosed participants and the number of participants with the diagnosis within the corresponding year, respectively. |
During the index period (2012 to 2023; up to 12 years)
|
|
Crude and Age-Adjusted Annual Incidence in Pediatric Ulcerative Colitis (UC)
기간: During the index period (2012 to 2023; up to 12 years)
|
The crude and age-adjusted annual incidence UC will be calculated in each calendar year. Annual incidence and the prevalence in the year of interest will be estimated using the number of newly diagnosed participants and the number of participants with the diagnosis within the corresponding year, respectively. |
During the index period (2012 to 2023; up to 12 years)
|
|
Crude and Age-Adjusted Annual Prevalence in Pediatric CD
기간: During the index period (2012 to 2023; up to 12 years)
|
The crude and age-adjusted annual prevalence CD will be calculated in each calendar year. Annual incidence and the prevalence in the year of interest will be estimated using the number of newly diagnosed participants and the number of participants with the diagnosis within the corresponding year, respectively. |
During the index period (2012 to 2023; up to 12 years)
|
|
Crude and Age-Adjusted Annual Prevalence in Pediatric UC
기간: During the index period (2012 to 2023; up to 12 years)
|
The crude and age-adjusted annual prevalence UC will be calculated in each calendar year. Annual incidence and the prevalence in the year of interest will be estimated using the number of newly diagnosed participants and the number of participants with the diagnosis within the corresponding year, respectively. |
During the index period (2012 to 2023; up to 12 years)
|
|
Incidence of CD by Age-Stratified Groups
기간: During the index period (2012 to 2023; up to 12 years)
|
Incidence of CD stratified by age-specific subgroups (0 to less than [<] 6 years old, 6 to <10 years old, and 10 to <18 years old) will be reported. |
During the index period (2012 to 2023; up to 12 years)
|
|
Incidence of UC by Age-Stratified Groups
기간: During the index period (2012 to 2023; up to 12 years)
|
Incidence of UC stratified by age-specific subgroups (0 to <6 years old, 6 to <10 years old, and 10 to <18 years old) will be reported. |
During the index period (2012 to 2023; up to 12 years)
|
|
Prevalence of CD by Age-Stratified Groups
기간: During the index period (2012 to 2023; up to 12 years)
|
Prevalence of CD stratified by age-specific subgroups (0 to <6 years old, 6 to <10 years old, and 10 to <18 years old) will be reported. |
During the index period (2012 to 2023; up to 12 years)
|
|
Prevalence of UC by Age-Stratified Groups
기간: During the index period (2012 to 2023; up to 12 years)
|
Prevalence of UC stratified by age-specific subgroups (0 to <6 years old, 6 to <10 years old, and 10 to <18 years old) will be reported. |
During the index period (2012 to 2023; up to 12 years)
|
|
Percentage of Participants Whose Primary Diagnosis Switched Between CD and UC
기간: During the index period (2012 to 2023; up to 12 years)
|
Percentage of participants whose primary diagnosis switched at least once between CD and UC during the follow-up period will be reported. |
During the index period (2012 to 2023; up to 12 years)
|
|
Initial Treatment Types by Age-Stratified Group
기간: From index date to follow-up (Up to 13 years)
|
Initial treatment types by age-stratified groups (0 to <6 years old, 6 to <10 years old, and 10 to <18 years old on the index date) will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Subsequent Treatment Sequences by Age-Stratified Group
기간: From index date to follow-up (Up to 13 years)
|
Subsequent treatment sequences by age-stratified groups (0 to <6 years old, 6 to <10 years old, and 10 to <18 years old on the index date) will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Cumulative Persistence Rates for Biologic Drugs
기간: From index date to follow-up (Up to 13 years)
|
Cumulative persistence rates for biologic drugs is defined as continuous use of the same biologic drug without a pre-defined biologic free interval (that is, 90 days or more) between prescription claims. |
From index date to follow-up (Up to 13 years)
|
|
Time to Discontinuation
기간: From index date to follow-up (Up to 13 years)
|
Discontinuation (non-persistence) will be defined as experiencing one of the following cases: stop: a case where biologic drug was prescribed with a gap of greater than or equal to (>=) 90 days from the discontinuation date of the previous prescription OR no further biologic drug was prescribed until the end of study period from the discontinuation date of the index drug; switch: a case where a different biologic drug was prescribed after the initial drug; re-initiation: a case where the same biologic drug was prescribed again after >=90 days. |
From index date to follow-up (Up to 13 years)
|
|
Number of Hospitalizations
기간: From index date to follow-up (Up to 13 years)
|
Number of hospitalizations both overall and by age groups will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Length of Hospitalization
기간: From index date to follow-up (Up to 13 years)
|
Length of hospitalization both overall and by age groups will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Number of Emergency Department (ED) Visit
기간: From index date to follow-up (Up to 13 years)
|
Number of ED visits both overall and by age groups will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Number of Outpatient Visits
기간: From index date to follow-up (Up to 13 years)
|
Number of outpatient visits both overall and by age groups will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Number of Inflammatory Bowel Disease (IBD) Related Surgeries
기간: From index date to follow-up (Up to 13 years)
|
Number of IBD related surgeries both overall and by age groups will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Number of Inpatient and Outpatient Visits to Non-Gastroenterology (GI) Departments
기간: From index date to follow-up (Up to 13 years)
|
Number of inpatient and outpatient visits to non-GI departments both overall and by age groups will be reported. |
From index date to follow-up (Up to 13 years)
|
|
Medical Costs
기간: From index date to follow-up (Up to 13 years)
|
Medical costs including inpatient, outpatient and pharmacy costs, both overall and by age groups, will be reported. |
From index date to follow-up (Up to 13 years)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Korea, Ltd. Clinical Trial, Janssen Korea, Ltd.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .